• Intracellular antibodies and biodegraders: Beyond small molecules and back again 

  Cardella, D; Sanchez-Guzman, D; Rabbitts, TH (ELSEVIER, 2023-09-01)
• Defining novel immune biomarkers of prognosis and immunotherapy sensitivity in gastro-oesophageal and colorectal cancers 

  Gerlinger M; Challoner, B; Gerlinger, M (Institute of Cancer Research (University Of London), 2023-11-28)

  Background Gastro-oesophageal adenocarcinomas (GOAs) frequently recur after resection; prognostic and predictive markers are absent. Mismatch repair-deficient (MMRd) GOAs have high mutational burden, are frequently ...
• Low-grade serous ovarian cancer: expert consensus report on the state of the science. 

  Grisham, RN; Slomovitz, BM; Andrews, N; Banerjee, S; Brown, J; et al. (BMJ PUBLISHING GROUP, 2023-09-04)

  Compared with high-grade serous carcinoma, low-grade serous carcinoma of the ovary or peritoneum is a less frequent epithelial ovarian cancer type that is poorly sensitive to chemotherapy and affects younger women, many ...
• Repeatability of quantitative individual lesion and total disease multiparametric whole-body MRI measurements in prostate cancer bone metastases. 

  Donners, R; Candito, A; Blackledge, M; Rata, M; Messiou, C; et al. (British Institute of Radiology, 2023-11-01)

  OBJECTIVES: To assess the repeatability of quantitative multiparametric whole-body MRI (mpWB-MRI) parameters in advanced prostate cancer (APC) bone metastases. METHODS: 1.5T MRI was performed twice on the same day in 10 ...
• Results of the SEL-I-METRY Phase II Trial on Resensitization of Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine Therapy. 

  Wadsley, J; Ainsworth, G; Coulson, AB; Garcez, K; Moss, L; et al. (MARY ANN LIEBERT, INC, 2023-09-01)
• Surgical Inflammation Alters Immune Response to Intraoperative Photodynamic Therapy. 

  Davis, RW; Klampatsa, A; Cramer, GM; Kim, MM; Miller, JM; et al. (American Association for Cancer Research (AACR), 2023-09-11)

  UNLABELLED: Surgical cytoreduction for patients with malignant pleural mesothelioma (MPM) is used for selected patients as a part of multi-modality management strategy. Our group has previously described the clinical use ...
• 

  Hitting the Target: Developing High-quality Evidence for Proton Beam Therapy Through Randomised Controlled Trials 

  Hudson, EM; Slevin, F; Biscombe, K; Brown, SR; Haviland, JS; et al. (Elsevier BV, 2023-11-03)
• 

  Quest markup for developing FAIR questionnaire modules for epidemiologic studies. 

  Russ, DE; Gerlanc, NM; Shen, B; Patel, B; de González, AB; et al. (Springer Science and Business Media LLC, 2023-10-25)

  BACKGROUND: Online questionnaires are commonly used to collect information from participants in epidemiological studies. This requires building questionnaires using machine-readable formats that can be delivered to study ...
• 

  Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study. 

  Bai, X; Shaheen, A; Grieco, C; d'Arienzo, PD; Mina, F; et al. (Elsevier BV, 2023-11-01)

  BACKGROUND: Both dabrafenib/trametinib (D/T) and anti-PD-1 monotherapy (PD-1) are approved adjuvant therapies for patients with stage III BRAF V600-mutant melanoma. However, there is still a lack of head-to-head comparative ...
• 

  Androgen receptor binding sites enabling genetic prediction of mortality due to prostate cancer in cancer-free subjects. 

  Ito, S; Liu, X; Ishikawa, Y; Conti, DD; Otomo, N; et al. (Springer Science and Business Media LLC, 2023-08-23)

  Prostate cancer (PrCa) is the second most common cancer worldwide in males. While strongly warranted, the prediction of mortality risk due to PrCa, especially before its development, is challenging. Here, we address this ...
• 

  ESR1 F404 mutations and acquired resistance to fulvestrant in ESR1 mutant breast cancer. 

  Kingston, B; Pearson, A; Herrera-Abreu, MT; Sim, L-X; Cutts, RJ; et al. (American Association for Cancer Research (AACR), 2023-11-20)

  Fulvestrant is used to treat patients with hormone receptor positive advanced breast cancer but acquired resistance is poorly understood. PlasmaMATCH Cohort A (NCT03182634) investigated the activity of fulvestrant in ...
• Ten-Year Outcomes of Stereotactic Body Radiotherapy for Oligometastatic Breast Cancer: Does Synchronous Oligometastatic Breast Cancer Benefit? 

  Nagpal, SK; Khabra, K; Ross, G; Kirby, AM (ELSEVIER SCIENCE LONDON, 2023-11-01)

  AIMS: The benefit of stereotactic body radiotherapy (SBRT) in metachronous oligometastatic breast cancer (OMBC) has previously been described and its use in current clinical practice is established. The role of SBRT in the ...
• Equality, diversity, and inclusion in oncology clinical trials: An audit of essential documents and data collection against INCLUDE under-served groups in a UK academic trial setting. 

  Patel, D; Kilburn, L; Fox, L; Hall, E; Bliss, J; et al.
• 

  Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results. 

  Diab, A; Gogas, H; Sandhu, S; Long, GV; Ascierto, PA; et al. (LIPPINCOTT WILLIAMS & WILKINS, 2023-10-20)

  PURPOSE: Despite marked advances in the treatment of unresectable or metastatic melanoma, the need for novel therapies remains. Bempegaldesleukin (BEMPEG), a pegylated interleukin-2 (IL-2) cytokine prodrug, demonstrated ...
• 

  Young oncologists' perspective on the role and future of the clinician-scientist in oncology. 

  Lim, KHJ; Westphalen, CB; Berghoff, AS; Cardone, C; Connolly, EA; et al. (Elsevier BV, 2023-10-01)
• 

  Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study. 

  Vergote, I; Van Nieuwenhuysen, E; O'Cearbhaill, RE; Westermann, A; Lorusso, D; et al. (American Society of Clinical Oncology (ASCO), 2023-08-31)

  PURPOSE: Tissue factor is highly expressed in cervical carcinoma and can be targeted by tisotumab vedotin (TV), an antibody-drug conjugate. This phase Ib/II study evaluated TV in combination with bevacizumab, pembrolizumab, ...
• 

  Integrating Artificial Intelligence Tools in the Clinical Research Setting: The Ovarian Cancer Use Case. 

  Escudero Sanchez, L; Buddenkotte, T; Al Sa'd, M; McCague, C; Darcy, J; et al. (MDPI, 2023-08-30)

  Artificial intelligence (AI) methods applied to healthcare problems have shown enormous potential to alleviate the burden of health services worldwide and to improve the accuracy and reproducibility of predictions. In ...
• 

  Development and Validation of a New BAG-1L-Specific Antibody to Quantify BAG-1L Protein Expression in Advanced Prostate Cancer. 

  Neeb, A; Figueiredo, I; Gurel, B; Nava Rodrigues, D; Rekowski, J; et al. (ELSEVIER SCIENCE INC, 2023-08-29)

  BCL-2-associated athanogene-1L (BAG-1L) is a critical co-regulator that binds to and enhances the transactivation function of the androgen receptor, leading to prostate cancer development and progression. Studies investigating ...
• 

  Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for Adenocarcinoma of the Prostate. 

  Roy, S; Romero, T; Michalski, JM; Feng, FY; Efstathiou, JA; et al. (American Society of Clinical Oncology (ASCO), 2023-11-10)

  PURPOSE: The surrogacy of biochemical recurrence (BCR) for overall survival (OS) in localized prostate cancer remains controversial. Herein, we evaluate the surrogacy of BCR using different surrogacy analytic methods. ...
• 

  Quality of life results in the UK TACT2 Trial of accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer: a multicentre, phase 3, open-label, randomised, controlled trial (CRUK/05/19) 

  Bliss, J

View more